Limits of Antidepressants and When to Consider TMS or Spravato at Clear Path Psychiatry
Living with depression can be exhausting—especially when you’ve tried “the usual meds” and still don’t feel like yourself. One reason this happens so often is simple: depression treatment isn’t one-size-fits-all. For many people, antidepressant medications are a helpful first step. For others, medications help some but not enough, or side effects become the limiting factor.
This article explains, in plain English, why depression medications sometimes stop short—and where Clear Path Psychiatry (Seattle) may fit by offering additional options such as TMS (transcranial magnetic stimulation) and Spravato (esketamine) for appropriate patients.
Safety note: This is educational information, not medical advice. If you have persistent depression symptoms or any thoughts of self-harm, the safest next step is an in-person evaluation with a qualified mental health clinician (or emergency care if you feel unsafe).
Quick summary: when medications help—and when they may not
Antidepressants (like SSRIs, SNRIs, and others) can be effective—especially for mild-to-moderate depression and alongside therapy and practical supports; many people need several weeks before meaningful change, and some need dose adjustments or a different medication (6). If depression hasn’t improved enough with standard approaches, clinic-based options may be discussed; at Clear Path Psychiatry, this includes TMS (a noninvasive brain-stimulation therapy) and Spravato (intranasal esketamine administered under medical supervision in a certified setting) (2,3,4,6). Only a qualified clinician can determine candidacy after a thorough evaluation.
Even when depression is treatable, it often takes a personalized plan—and sometimes next-step options—to find what works for you.
Why “my depression meds aren’t working” is so common
Depression care has many moving parts. Two people can share the same diagnosis and still need different strategies. Symptoms can overlap with (or be influenced by) sleep issues, anxiety, trauma, medical conditions, substance use, or major life stressors—so a plan that helps one person may miss the mark for another.
A stepwise approach is typical: a clinician may adjust the medication choice, the dose, the timing, or whether to combine treatments (for example, medication plus psychotherapy, or medication plus another intervention).
Antidepressants typically aren’t instant. Many people need several weeks to see meaningful improvement, and some need a change in medication or dose to find a better fit. Commonly cited timeframes are about 4–8 weeks for full effect, with individual variation (6).
If progress has stalled despite careful trials, that’s a good signal to revisit the plan with your clinician.
What medications can do for depression symptoms (and their limits)
Common medication categories include SSRIs/SNRIs (often first-line) (6), atypical antidepressants selected based on symptoms or side effects (6), and augmentation strategies that add another medication to improve response (1,6).
Real-world limitations: relief is delayed and often takes weeks (6); trial-and-error can be discouraging (1); side effects may affect energy, sleep, weight, or sexual function (6); partial response is common—“some better,” but not enough for day-to-day functioning (1). A useful question is: Are my symptoms meaningfully better—or mostly unchanged despite an adequate trial?
If you’re “better but not well,” it’s reasonable to ask about additional, evidence-based options.
Clear Path Psychiatry in plain English: what it is (and what it isn’t)
What Clear Path Psychiatry offers: TMS (transcranial magnetic stimulation), a noninvasive treatment using magnetic pulses to stimulate brain regions involved in mood (3,4); Spravato (esketamine), an FDA-approved intranasal medication administered only in a certified setting under a REMS program, typically used with an oral antidepressant (2,6).
If you want a clinic overview, see: Clear Path Psychiatry – TMS: https://www.clearpathpsychiatry.com/treatments/transcranial-magnetic-stimulation and Clear Path Psychiatry – FAQ: https://www.clearpathpsychiatry.com/faq
What Clear Path Psychiatry is not: a guarantee of results; universally “medication-free” (Spravato is a medication, and many people continue oral antidepressants) (2,6); or a replacement for standard care in all cases (many do well with first-line treatments; others may benefit from combined or next-step options) (1,6). Note: TMS requires repeated clinic visits over multiple weeks; Spravato also involves recurring clinic appointments with on-site observation (2,4,6).
Think of Clear Path Psychiatry as a place to discuss additional options—not as a one-size-fits-all solution.
Medications and clinic-based options: a practical, side-by-side look
Antidepressant medications (first-line for many)
Targets brain signaling over time; advantages include wide availability, effectiveness for many with mild-to-moderate depression, and compatibility with psychotherapy (6); considerations include time to effect, variable side effects, and the possibility of multiple trials (6).
TMS (offered at Clear Path Psychiatry)
Targets specific brain regions via noninvasive magnetic pulses; advantages include an option for some adults without adequate results from medications, no anesthesia, and general tolerability (4); considerations include repeated clinic sessions over several weeks, common headache or scalp discomfort, rare seizure risk, and no guaranteed result (4).
Spravato (esketamine) (offered at Clear Path Psychiatry)
Targets glutamatergic pathways via intranasal dosing in a certified clinic; advantages include an option for specific adults with treatment-resistant depression when used with an oral antidepressant and on-site monitoring (6); considerations include REMS-only availability, observation for sedation, dissociation, and blood-pressure changes, required transportation planning with no driving until the next day after a restful sleep, candidacy based on history and safety screening, and no guaranteed result (6).
Important note on candidacy thresholds
Criteria vary by treatment, device labeling, insurer, and clinical guidelines. For example, Spravato use in treatment-resistant depression generally involves inadequate response to at least two oral antidepressants in the current episode, and it is used concurrently with an oral antidepressant. TMS eligibility varies by device labeling and insurer policies. Only a qualified clinician can determine appropriateness based on current labeling and your evaluation (1,4,6).
Each option has strengths and trade-offs—your history, goals, and safety profile guide the choice.
What the evidence says about next-step options (not specific to any one clinic)
Major medical resources describe treatment-resistant depression (TRD) as depression that hasn’t improved adequately after appropriate treatment attempts. Stepped-care models include medication optimization, psychotherapy, augmentation, and brain-stimulation therapies such as TMS (1,4).
In research and practice, “response” usually means measurable symptom reduction rather than full remission. Using symptom scales and structured check-ins helps you and your clinician tell whether the plan is working rather than guessing (6).
Evidence supports next-step options for some people—your clinician can help decide if and when to consider them.
Safety and side effects: comparing “daily meds” and “clinic-based” risks
Medication-related considerations
Requires daily adherence; side effects can affect energy, sleep, weight, or sexual function (varies by medication and person) (6); waiting weeks to see if a change helps is common (6).
TMS: safety context
Noninvasive and generally well tolerated; common side effects include headache or scalp discomfort; rare but serious risk is seizure; requires repeated sessions and follow-up; no guaranteed result (4).
Spravato (esketamine): safety context
Administered only in a REMS-certified healthcare setting with on-site monitoring for sedation, dissociation, and blood-pressure changes after each dose; patients must plan safe transportation and should not drive or operate machinery until the next day after a restful sleep; typically used with an oral antidepressant; candidacy depends on history and safety screening (6).
Safety is about fit—your personal risks, supports, and schedule should inform the plan.
Candidacy: questions to discuss with a qualified clinician
Step 1 — Clarify the diagnosis
Confirm whether symptoms fit major depression, bipolar depression, anxiety, trauma-related conditions, or something else; review medical and substance-related factors; ensure “what didn’t work” reflects adequate dose, duration, and follow-up (6).
Step 2 — Review what you’ve already tried
List medications, doses, and durations; note any benefits; identify limiting side effects; consider whether psychotherapy and practical supports have been part of the plan (6).
Step 3 — Discuss eligibility and safety
TMS and esketamine have different indications, labeling, and safety requirements; Spravato use in treatment-resistant depression generally follows inadequate response to at least two oral antidepressants in the current episode and concurrent use of an oral antidepressant, with observation and transportation planning required (6); TMS criteria vary by device and insurer, and frequency/duration of sessions require scheduling commitment (4); only a qualified clinician can determine candidacy after a full evaluation.
If you’re not in Seattle, ask your local mental health clinician about TMS or esketamine referrals available in your area.
Eligibility is individualized—let your clinician guide this decision.
What to expect if you move beyond medications
A typical patient journey
1) Diagnostic evaluation and treatment history review; 2) Plan refinement: optimize medication/therapy and/or discuss TMS or esketamine; 3) Structured treatment course (for example, TMS involves repeated sessions over several weeks; Spravato involves clinic visits with observation) (2,4,6); 4) Follow-up to track response and side effects; 5) Maintenance plan to support sustained improvement.
Questions to bring to your visit
How do we define an adequate medication trial in my case (1,6)? Based on my history, am I a potential candidate for TMS or esketamine—and what would screening involve (4,6)? What time commitment and logistics (transportation, observation, time off work) should I expect (2,4,6)? How will we measure success—symptoms, functioning, and quality of life (6)?
Tracking progress in a way you can feel
Use brief weekly check-ins on sleep, energy, interest, concentration, and daily functioning; consider standardized depression scales (for example, PHQ-9) to make changes visible over time (6).
Clear goals and simple tracking make it easier to see what’s helping—and what to adjust.
FAQs
Why do antidepressants help some people but not everyone?
Response varies, and antidepressants often take weeks to work. Some people have only partial improvement or limiting side effects, which is why clinicians may discuss other options (6).
Does it mean my depression is “untreatable” if meds haven’t worked?
Not necessarily. “Treatment-resistant depression” usually means you haven’t improved enough after appropriate attempts—not that you can’t get better. Additional strategies, including brain-stimulation therapies like TMS, may be considered (1,4).
How long should I try medication before considering TMS or Spravato?
It depends on your history. Many clinicians consider next-step options after adequate medication trials (right dose, sufficient duration, with follow-up). Criteria for Spravato and TMS differ and must be confirmed against current labeling and a clinical evaluation (1,4,6).
Does Clear Path Psychiatry replace medication treatment?
Not universally. Clear Path offers TMS (a noninvasive procedure) and Spravato (a medication). Many patients continue oral antidepressants as part of a broader plan (2,6).
Use your clinician’s guidance—timing and fit depend on your specific history and goals.
Conclusion: match treatment to your diagnosis, history, and goals
If your symptoms improve substantially with antidepressants, medication may be the right foundation. But if you’ve given medication a fair trial and you’re still not where you need to be, it’s reasonable to discuss next-step options. A structured review of your diagnosis and treatment history can help you and your clinician decide whether to optimize medication, add psychotherapy, or consider options offered at clinics like Clear Path Psychiatry, including TMS and Spravato when appropriate.
The most effective plan is the one that fits you.
References
1. Mayo Clinic. Treatment-resistant depression. https://www.mayoclinic.org/diseases-conditions/depression/in-depth/treatment-resistant-depression/art-20044324
2. Clear Path Psychiatry. FAQ. https://www.clearpathpsychiatry.com/faq
3. Clear Path Psychiatry. Transcranial Magnetic Stimulation (TMS). https://www.clearpathpsychiatry.com/treatments/transcranial-magnetic-stimulation
4. National Institute of Mental Health (NIMH). Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies
6. National Institute of Mental Health (NIMH). Mental Health Medications. https://www.nimh.nih.gov/health/topics/mental-health-medications
This article is for educational purposes only and is not medical advice. Please consult a qualified healthcare provider for diagnosis and treatment.
Dr. David G. Dillard
Author
Share it with others!
